|Novel data‐mining methodologies for adverse drug event discovery and analysis|
R Harpaz, W DuMouchel, NH Shah, D Madigan, P Ryan, C Friedman
Clinical Pharmacology & Therapeutics 91 (6), 1010-1021, 2012
|Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership|
PE Stang, PB Ryan, JA Racoosin, JM Overhage, AG Hartzema, C Reich, ...
Annals of internal medicine 153 (9), 600-606, 2010
|Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers|
G Hripcsak, JD Duke, NH Shah, CG Reich, V Huser, MJ Schuemie, ...
Studies in health technology and informatics 216, 574, 2015
|Validation of a common data model for active safety surveillance research|
JM Overhage, PB Ryan, CG Reich, AG Hartzema, PE Stang
Journal of the American Medical Informatics Association 19 (1), 54-60, 2012
|Performance of pharmacovigilance signal‐detection algorithms for the FDA adverse event reporting system|
R Harpaz, W DuMouchel, P LePendu, A Bauer‐Mehren, P Ryan, ...
Clinical Pharmacology & Therapeutics 93 (6), 539-546, 2013
|Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership|
PB Ryan, D Madigan, PE Stang, J Marc Overhage, JA Racoosin, ...
Statistics in medicine 31 (30), 4401-4415, 2012
|Evaluating the impact of database heterogeneity on observational study results|
D Madigan, PB Ryan, M Schuemie, PE Stang, JM Overhage, ...
American journal of epidemiology 178 (4), 645-651, 2013
|Characterizing treatment pathways at scale using the OHDSI network|
G Hripcsak, PB Ryan, JD Duke, NH Shah, RW Park, V Huser, MA Suchard, ...
Proceedings of the National Academy of Sciences 113 (27), 7329-7336, 2016
|Control of reproductive floral organ identity specification in Arabidopsis by the C function regulator AGAMOUS|
DS Ó’Maoiléidigh, SE Wuest, L Rae, A Raganelli, PT Ryan, ...
The Plant Cell 25 (7), 2482-2503, 2013
|Interpreting observational studies: why empirical calibration is needed to correct p‐values|
MJ Schuemie, PB Ryan, W DuMouchel, MA Suchard, D Madigan
Statistics in medicine 33 (2), 209-218, 2014
|Defining a reference set to support methodological research in drug safety|
PB Ryan, MJ Schuemie, E Welebob, J Duke, S Valentine, AG Hartzema
Drug safety 36 (1), 33-47, 2013
|A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data|
MG Kahn, TJ Callahan, J Barnard, AE Bauck, J Brown, BN Davidson, ...
Egems 4 (1), 2016
|Disproportionality methods for pharmacovigilance in longitudinal observational databases|
I Zorych, D Madigan, P Ryan, A Bate
Statistical methods in medical research 22 (1), 39-56, 2013
|Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases|
SJ Reisinger, PB Ryan, DJ O'Hara, GE Powell, JL Painter, EN Pattishall, ...
Journal of the American Medical Informatics Association 17 (6), 652-662, 2010
|A comparison of the empirical performance of methods for a risk identification system|
PB Ryan, PE Stang, JM Overhage, MA Suchard, AG Hartzema, ...
Drug safety 36 (1), 143-158, 2013
|A systematic statistical approach to evaluating evidence from observational studies|
D Madigan, PE Stang, JA Berlin, M Schuemie, JM Overhage, MA Suchard, ...
Annual Review of Statistics and Its Application 1, 11-39, 2014
|Feasibility and utility of applications of the common data model to multiple, disparate observational health databases|
EA Voss, R Makadia, A Matcho, Q Ma, C Knoll, M Schuemie, FJ DeFalco, ...
Journal of the American Medical Informatics Association 22 (3), 553-564, 2015
|Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 …|
PB Ryan, JB Buse, MJ Schuemie, F DeFalco, Z Yuan, PE Stang, JA Berlin, ...
Diabetes, Obesity and Metabolism 20 (11), 2585-2597, 2018
|Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium‐glucose co‐transporter‐2 inhibitors in the USA: a retrospective cohort study|
Z Yuan, FJ DeFalco, PB Ryan, MJ Schuemie, PE Stang, JA Berlin, ...
Diabetes, Obesity and Metabolism 20 (3), 582-589, 2018
|Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases|
C Reich, PB Ryan, PE Stang, M Rocca
Journal of biomedical informatics 45 (4), 689-696, 2012